BioSpace News Archive

Ginkgo Bioworks today announced a new collaboration with Merck, known as MSD outside of the United States and Canada, focused on improving biologic manufacturing.

Tabula Rasa HealthCare, Inc.® today reported financial results for the second quarter ended June 30, 2023.

Envista Holdings Corporation announced its intention to offer, subject to market and other conditions, $435,000,000 in aggregate principal amount of Convertible Senior Notes due 2028 in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended.

Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS) disorders, today reported financial results for the second quarter ended June 30, 2023 and provided recent business highlights.

Apogee Therapeutics, Inc. today announced that it has initiated dosing of healthy volunteers in its first clinical trial for APG777, its lead product candidate being developed as a frontline treatment for moderate-to-severe AD and other inflammatory diseases.

Gracell Biotechnologies Announces Up to $150 Million Private Placement Financing Joined by a Syndicate of Premier Healthcare Investors.

Avalyn Pharma Inc., a clinical-stage biopharmaceutical company focused on development of targeted therapies for life-threatening pulmonary diseases, today announced that it has appointed Howard M. Lazarus, M.D., FCCP, to the newly created position of chief medical officer.

Indaptus Therapeutics, Inc. (Nasdaq: INDP), a biotechnology company focused on discovering and developing transformative therapeutics for patients, announces the appointment of Roger Waltzman, M.D. as its Chief Medical Officer, effective August 7, 2023.

Voyager Therapeutics, Inc. today announced the appointment of Beth Shafer, Ph.D., M.A., M.Phil., as Chief Business Officer (CBO).

Rhythm Pharmaceuticals, Inc. today announced that the French National Agency for Medicines and Health Products Safety (ANSM) and French National Authority for Health (HAS) have granted pre-marketing early access authorization AP1 (Autorisation d’Accès Précoce), for IMCIVREE® (setmelanotide), an MC4R agonist, for patients with lesional hypothalamic obesity.